Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate.

Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, Teunissen JJ, de Jong M, van Lom K, de Herder WW, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1138-46. doi: 10.1007/s00259-009-1072-6. Epub 2009 Feb 27.

2.

Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.

Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, Sundin A, Lundqvist H, Lubberink M.

J Nucl Med. 2013 Jan;54(1):33-41. doi: 10.2967/jnumed.112.107524. Epub 2012 Dec 7.

3.

Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?

Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1346-51. Epub 2006 Jul 18.

PMID:
16847654
4.

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.

Bergsma H, Konijnenberg MW, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Franssen GJ, van Eijck CH, Krenning EP, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):453-63. doi: 10.1007/s00259-015-3193-4. Epub 2015 Sep 30.

5.

Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate.

Sandström M, Garske U, Granberg D, Sundin A, Lundqvist H.

Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):212-25. doi: 10.1007/s00259-009-1216-8. Epub 2009 Sep 2.

PMID:
19727718
6.

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP.

Semin Nucl Med. 2002 Apr;32(2):133-40. Review.

PMID:
11965608
7.

Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.

Rolleman EJ, Forrer F, Bernard B, Bijster M, Vermeij M, Valkema R, Krenning EP, de Jong M.

Eur J Nucl Med Mol Imaging. 2007 May;34(5):763-71. Epub 2006 Dec 5.

PMID:
17146655
8.

Comparison of 111In-[DTPA0]Octreotide Versus Non Carrier Added 177Lu- [DOTA0,Tyr3]-Octreotate Efficacy in Patients With GEP-NET Treated Intra-arterially for Liver Metastases.

Limouris GS, Poulantzas V, Trompoukis N, Karfis I, Chondrogiannis S, Triantafyllou N, Gennimata V, Moulopoulou LE, Patsouris E, Nikou G, Michalaki V, Fragulidis G, Paphiti M, McCready RV, Colletti PM, Cook GJ, Rubello D.

Clin Nucl Med. 2016 Mar;41(3):194-200. doi: 10.1097/RLU.0000000000001096.

PMID:
26673241
9.

Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs.

Müller C, Forrer F, Bernard BF, Melis M, Konijnenberg M, Krenning EP, de Jong M.

Cancer Biother Radiopharm. 2007 Feb;22(1):151-9.

PMID:
17627424
10.

Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.

Sainz-Esteban A, Prasad V, Schuchardt C, Zachert C, Carril JM, Baum RP.

Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):501-11. doi: 10.1007/s00259-011-2003-x. Epub 2011 Dec 20.

PMID:
22183108
11.

177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.

Garkavij M, Nickel M, Sjögreen-Gleisner K, Ljungberg M, Ohlsson T, Wingårdh K, Strand SE, Tennvall J.

Cancer. 2010 Feb 15;116(4 Suppl):1084-92. doi: 10.1002/cncr.24796.

12.

Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.

Chalkia MT, Stefanoyiannis AP, Chatziioannou SN, Round WH, Efstathopoulos EP, Nikiforidis GC.

Australas Phys Eng Sci Med. 2015 Mar;38(1):7-22. doi: 10.1007/s13246-014-0312-7. Epub 2014 Nov 27. Review.

PMID:
25427548
13.

Analysis of 177Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors.

Denoyer D, Lobachevsky P, Jackson P, Thompson M, Martin OA, Hicks RJ.

J Nucl Med. 2015 Apr;56(4):505-11. doi: 10.2967/jnumed.114.145581. Epub 2015 Feb 26.

14.

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.

Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP.

Endocr Relat Cancer. 2010 Jan 29;17(1):R53-73. doi: 10.1677/ERC-09-0078. Print 2010 Mar. Review.

15.

Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy.

Baechler S, Hobbs RF, Boubaker A, Buchegger F, He B, Frey EC, Sgouros G.

Med Phys. 2012 Oct;39(10):6118-28. doi: 10.1118/1.4752213.

16.

Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.

Swärd C, Bernhardt P, Johanson V, Schmitt A, Ahlman H, Stridsberg M, Forssell-Aronsson E, Nilsson O, Kölby L.

Cancer Biother Radiopharm. 2008 Feb;23(1):114-20. doi: 10.1089/cbr.2007.0421.

PMID:
18298335
17.

Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.

Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, Fischer R, Rivier JE, Reubi JC, Maecke HR, Weber WA.

J Nucl Med. 2014 Aug;55(8):1248-52. doi: 10.2967/jnumed.114.138834. Epub 2014 Jun 24.

18.

Renal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷Lu-DOTATATE treatment.

Svensson J, Berg G, Wängberg B, Larsson M, Forssell-Aronsson E, Bernhardt P.

Eur J Nucl Med Mol Imaging. 2015 May;42(6):947-55. doi: 10.1007/s00259-015-3001-1. Epub 2015 Feb 6.

19.

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.

Barone R, Walrand S, Konijnenberg M, Valkema R, Kvols LK, Krenning EP, Pauwels S, Jamar F.

Nucl Med Commun. 2008 Mar;29(3):283-90. doi: 10.1097/MNM.0b013e3282f3d03e.

PMID:
18349800
20.

The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.

Breeman WA, van der Wansem K, Bernard BF, van Gameren A, Erion JL, Visser TJ, Krenning EP, de Jong M.

Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):312-5. Epub 2002 Nov 29.

PMID:
12552352

Supplemental Content

Support Center